Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-05-22 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 118 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document best fits the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2020-05-22 English
NATCO supports Columbia University's clinical trial of chloroquine phosphate to prevent symptomatic Covid-19 infections
Regulatory Filings
2020-05-22 English
Press Release
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 176 characters, indicating it is extremely short and contains no report content. It does not contain any financial statements, regulatory information, or announcements. Given the lack of content, this document cannot be classified as a report or announcement type and falls under the fallback category for miscellaneous filings.
2020-05-20 English
NATCO's VIZAG FORMULATION FACILITY RECEIVES EIR
Regulatory Filings
2020-05-20 English
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text content. The true document length is only 251 characters, which is very short and contains no financial data, report content, or announcements. It does not contain any report, announcement, or regulatory filing information. Given the lack of content, the document cannot be classified as a report or announcement type and defaults to the fallback category for miscellaneous filings that do not fit elsewhere.
2020-05-19 English
NATCO's Chloroquine for International Study to prevent SARS-CoV-2 infection In Frontline Healthcare Workers
Regulatory Filings
2020-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.